Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | -3.14% | -10.20% | +146.40% |
05-08 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
04-16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+146.40% | 40.98M | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- LEXX Stock
- News Lexaria Bioscience Corp.
- Lexaria Bioscience Set to File Investigational New Drug Application for Hypertension Trial Within 45 Days